Geneos Wealth Management’s CureVac CVAC Stock Holding History

Geneos Wealth Management’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25	Closed	-$1K	–	2787
2021 Q3	$1K	Hold	25	–	–	﹤0.01%	2723
2021 Q2	$1K	Buy	+25	New	+$2.5K	﹤0.01%	2739

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Geneos Wealth Management's CVAC Position: Q4 2021 in Review

Geneos Wealth Management sold out of CureVac (CVAC) in Q4 2021, closing a stake of 25 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in CVAC in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 103 funds tracked by Wall St. Rank hold CVAC as of Q4 2021.

Geneos Wealth Management reported no remaining CureVac position as of Q4 2021 after selling out during the quarter.
Geneos Wealth Management sold 25 CureVac shares in Q4 2021, an estimated $1K.
Geneos Wealth Management first reported a position in CureVac in Q2 2021 and held it in 2 quarters.
Geneos Wealth Management's CureVac position peaked at $1K in Q3 2021.
103 funds tracked by Wall St. Rank held CureVac as of Q4 2021.

Based on Geneos Wealth Management's 13F filing for Q4 2021, filed 9 Feb 2022.